Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase II, Randomised, Multicentre Study With Two Treatment Arms (R-COMP Versus R-CHOP) in Newly Diagnosed Elderly Patients (≥60 Years) With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb.

Authors not listed

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · 2013

Dysbiosis Human Randomized controlled trial

Abstract

The Phase II study proposed here assesses the hypothesis that replacing doxorubicin by Myocet® in the R-CHOP regimen would yield comparable antitumour efficacy with a lower cardiotoxicity for first-line treatment in elderly patients with non-localised DLBCL/Follicular lymphoma grade IIIb

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-19 MST

Cite this

APA

Anonymous. (2013). Phase II, Randomised, Multicentre Study With Two Treatment Arms (R-COMP Versus R-CHOP) in Newly Diagnosed Elderly Patients (≥60 Years) With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb. <em>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</em>. https://clinicaltrials.gov/study/NCT02012088

Vancouver

Anonymous. Phase II, Randomised, Multicentre Study With Two Treatment Arms (R-COMP Versus R-CHOP) in Newly Diagnosed Elderly Patients (≥60 Years) With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb. Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea. 2013.

BibTeX

@misc{anon2013PhaseI, title = {Phase II, Randomised, Multicentre Study With Two Treatment Arms (R-COMP Versus R-CHOP) in Newly Diagnosed Elderly Patients (≥60 Years) With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb.}, author = {Anonymous}, journal = {Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea}, year = {2013}, }